KXAN

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to ...
Seeking Alpha

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

These results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE) -- via ...
Benzinga.com

Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

PaxMedica plans to fund a global supply chain for PAX-101 and further advance research and trials for Autism Spectrum Disorder. A successful review and approval of the NDA could further qualify the ...
KTLA

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously ...

How a new drug kills sleeping sickness parasites by damaging their DNA

Trypanosomatids are parasites that can result in more than 1 billion potentially fatal infections per year globally. In ...
The Scientist

African Sleeping Sickness: A Recurring Epidemic

Thanks to efforts by MSF, the immediate future for those with sleeping sickness looks considerably brighter than the recent past, but the long-term prognosis isn't clear. The story of the reemergence ...